News | February 10, 2026
Neuland Laboratories reports Rs 1,264.5 crore revenue for 9MFY26
The revenues this quarter are in line with the outlook we envisaged for the year
The revenues this quarter are in line with the outlook we envisaged for the year
The company’s EBITDA margin remained resilient above 20%
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
HCG clinicians contributing to one of the largest bodies of oncology research from India
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
Call it one of the most striking turnarounds in the Indian pharma sector this fiscal year
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
